Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Jul 16 2026 | Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia Industry News Industry Read More Jul 15 2026 | 15 States Have Five or Fewer Advanced Heart Failure Specialists, New Study in the Journal of Cardiac Failure-Intersection Finds HFSA News Journal of Cardiac Failure Press Release Read More Jul 14 2026 | July Issue of Journal of Cardiac Failure Highlights New Strategies to Predict Decompensation, Identify Risk in HFpEF, and Refine Device-Based Therapies HFSA News Journal of Cardiac Failure Press Release Read More Jul 12 2026 | HFSA President's Update: July 2026 HFSA News President's Updates Read More Jul 2 2026 | Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM Industry News Industry Read More Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
Jul 16 2026 | Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia Industry News Industry Read More
Jul 15 2026 | 15 States Have Five or Fewer Advanced Heart Failure Specialists, New Study in the Journal of Cardiac Failure-Intersection Finds HFSA News Journal of Cardiac Failure Press Release Read More
Jul 14 2026 | July Issue of Journal of Cardiac Failure Highlights New Strategies to Predict Decompensation, Identify Risk in HFpEF, and Refine Device-Based Therapies HFSA News Journal of Cardiac Failure Press Release Read More
Jul 2 2026 | Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM Industry News Industry Read More
